Specialty Pharmacy

The risk of developing liver cancer is similar with direct-acting antiviral drugs or interferon therapy for hepatitis C virus.

Attendees of the National Association of Specialty Pharmacy annual meeting have the chance to see the nation’s capital during downtime.

Cyltezo approved for the same indications as Humira, including rheumatoid arthritis, psoriatic arthritis, and Crohn’s disease.

The $2 million grant seeks to help establish guidelines for further development of treatments for HIV.

Alcohol consumption results in more than $150 million spent on breast cancer annually.

Top news of the day from across the healthcare landscape.

Experimental drug shows evidence of lowering cholesterol, reducing risk of cardiovascular disease, and potentially treating lung cancer.

Faslodex reduced disease progression by 20% among women with HR+, HER2- advanced breast cancer.

A decision on the approval of obinutuzumab is expected by December 23, 2017.

Top news of the day from across the health care landscape.

Findings may lead to new targeted treatment options for HIV infection.

Prophylactic mastectomy for ovarian cancer survivors with BRCA mutations may not improve survival.

Hormone therapy is recommended to treat menopause symptoms, but is not recommended for breast cancer survivors.

The findings offer a new pathway for developing treatments for diseases such as amyotrophic lateral sclerosis.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Top news of the week from Specialty Pharmacy Times.

Treatments for hepatitis C, hemophilia, and cholesterol among specialty drugs approved for new indications this year.

Women who worked the night shift found to have a greater risk of developing breast cancer.

West Virginia University program seeks to combat the spread of infectious diseases via injection drug use.

New ulcerative colitis and Crohn’s disease cases were uncommon in plaque psoriasis patients administered ixekizumab.

Top news of the day from across the health care landscape.

Study findings may improve treatment options for autoimmune disease.

Emicizumab prophylaxis is designed to bring together factors IXa and X to restore the blood clotting process.

Risk of death from MS higher among men in military across 3 successive decades.

Inhibiting heparanase observed to inhibit medulloblastoma cells.

Marcus H. Snow, MD, of the University of Nebraska Medical Center, discusses the importance of the treat-to target-strategy versus the non-targeted therapeutic approach in patients with rheumatoid arthritis.

HIV rebound detected within 1 day before delivery in 50% of study participants.

Top news of the day from across the health care landscape.